MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company’s board with complementary expertise in public company leadership, capital markets, and medical device commercialization. “These appointments reflect our cont ...

Core Insights - Nuwellis, Inc. has appointed Carisa Schultz as Chief Financial Officer, effective February 2, 2026, to enhance its financial leadership in the medical technology sector focused on precision cardiorenal care [1][4]. Company Overview - Nuwellis, Inc. is a medical technology company that develops precision fluid management technologies aimed at improving patient care across the cardiorenal continuum, addressing both acute and chronic conditions [4]. - The company's product portfolio includes both commercially available and development-stage technologies that focus on safety, precision, and scalability for various patient populations [4]. Leadership Experience - Carisa Schultz has extensive experience in healthcare finance, having served as Vice President of Finance at NeueHealth, where she led enterprise finance, treasury, and corporate development [2]. - Schultz's background includes roles at Boston Scientific and various leadership positions in public and private healthcare organizations, along with experience in Big Four public accounting [3]. Product Highlight - The Aquadex SmartFlow® System is designed to remove excess fluid from patients suffering from hypervolemia, with indications for both temporary and extended use in adult and pediatric patients [5].

Core Viewpoint - Nuwellis, Inc. has entered into a Securities Purchase Agreement to acquire Rendiatech Ltd., enhancing its capabilities in real-time kidney function monitoring and expanding its cardiorenal platform [1][2]. Group 1: Transaction Details - The acquisition of Rendiatech is expected to close upon meeting customary closing conditions, positioning Nuwellis to broaden its portfolio into real-time renal diagnostics [1][5]. - The transaction has been approved by the boards of directors of both Nuwellis and Rendiatech [5]. Group 2: Strategic Implications - This acquisition represents a strategic move for Nuwellis, allowing the company to extend its capabilities beyond therapeutic fluid management into real-time renal monitoring, which aligns with its long-term vision [2][4]. - Nuwellis plans to leverage its existing commercial infrastructure and clinical relationships to integrate Rendiatech's technology effectively [4]. Group 3: Technology Overview - Rendiatech's Clarity™ system offers automated, continuous renal monitoring through precise urine-output measurement, aiming to replace manual collection methods [3][9]. - The addition of the Clarity system is expected to lay the groundwork for future advancements in urine-based analytics and comprehensive kidney function assessment [3].

Core Viewpoint - Nuwellis, Inc. has appointed Katharyn Field and Mika Grasso to its board of directors, effective January 21, 2026, while three members resigned from the board, with no disagreements reported [1][4][5]. Group 1: Board Appointments - Katharyn Field is the CEO of ISpecimen Inc. and has held various leadership roles in other companies, including Halo Collective and Marimed Inc. She holds an MBA from Columbia Business School and a BA from Stanford University [2]. - Mika Grasso is an Investment Manager at a private family office with prior experience at Zions Capital Markets, Paulson Investment Company, Goldman Sachs, and Power Systems Management. He holds an MS in Finance and a BS in Business Administration from the University of Colorado Boulder [3]. Group 2: Board Resignations - Dave McDonald, Mike McCormick, and Dr. Maria Costanzo resigned from the board effective January 21, 2026, with the company confirming that these resignations were not due to any disagreements regarding operations or policies [4][5]. Group 3: Company Overview - Nuwellis, Inc. is a medical technology company focused on precision fluid management technologies for cardiorenal care, developing solutions for both acute and chronic care settings [6]. - The company's portfolio includes technologies addressing complex cardiorenal conditions, emphasizing safety, precision, and scalability [6].

Core Insights - Nuwellis, Inc. has received a notice of allowance for a new patent related to advanced safety mechanisms for blood return line clamps in extracorporeal blood filtration systems, specifically for the Vivian Pediatric Continuous Renal Replacement Therapy (CRRT) System [1][3] - The patented technology enhances safety by dynamically adjusting clamping force based on environmental factors and improving material stability through thermal insulation [2] - The company emphasizes its commitment to pediatric innovation and safety, with a growing portfolio of intellectual property supporting the Vivian system [3][4] Company Overview - Nuwellis, Inc. is a medical technology company focused on solutions for patients with cardio-renal conditions, headquartered in Minneapolis with a subsidiary in Ireland [6] - The company is dedicated to transforming the lives of patients suffering from fluid overload through innovative therapies, including the Aquadex SmartFlow system [6][7] Product Details - The Aquadex SmartFlow system is designed for ultrafiltration therapy in patients with fluid overload, indicated for both temporary and extended use in adults and pediatric patients weighing 20 kg or more [7] - The Vivian system is a pediatric CRRT platform designed for neonates and children, featuring integrated sensors for real-time monitoring and multiple therapy options [8]

Core Viewpoint - Nuwellis, Inc. has announced a postponement of its 2025 second quarter earnings release and conference call, originally set for August 12, 2025, due to the need for additional time to complete valuations and audit procedures [1] Company Overview - Nuwellis, Inc. is a medical technology company focused on fluid management, specifically targeting patients suffering from fluid overload [3] - The company is headquartered in Minneapolis and has a wholly owned subsidiary in Ireland [3] Product Information - The Aquadex SmartFlow® system is designed for ultrafiltration therapy, providing a clinically proven method to remove excess fluid from patients with hypervolemia [4] - The system is indicated for temporary use (up to 8 hours) or extended use (longer than 8 hours) in adult and pediatric patients weighing 20 kg or more, whose fluid overload is unresponsive to medical management [4] Upcoming Events - A conference call and webcast to discuss financial results and provide a general business update is scheduled for 9:00 AM ET on August 14, 2025 [1]